The Effect of Modified Porcine Surfactant Alone or in Combination with Polymyxin B on Lung Homeostasis in LPS-Challenged and Mechanically Ventilated Adult Rats

The study aimed to prove the hypothesis that exogenous surfactant and an antibiotic polymyxin B (PxB) can more effectively reduce lipopolysaccharide (LPS)-induced acute lung injury (ALI) than surfactant treatment alone, and to evaluate the effect of this treatment on the gene expression of surfactant proteins (SPs). Anesthetized rats were intratracheally instilled with different doses of LPS to induce ALI. Animals with LPS 500 μg/kg have been treated with exogenous surfactant (poractant alfa, Curosurf®, 50 mg PL/kg b.w.) or surfactant with PxB 1% w.w. (PSUR + PxB) and mechanically ventilated for 5 hrs. LPS at 500 μg/kg increased lung edema, oxidative stress, and the levels of proinflammatory mediators in lung tissue and bronchoalveolar lavage fluid (BALF). PSUR reduced lung edema and oxidative stress in the lungs and IL-6 in BALF. This effect was further potentiated by PxB added to PSUR. Exogenous surfactant enhanced the gene expression of SP-A, SP-B, and SP-C, however, gene expression for all SPs was reduced after treatment with PSUR + PxB. In mechanically ventilated rats with LPS-induced ALI, the positive effect of exogenous surfactant on inflammation and oxidative stress was potentiated with PxB. Due to the tendency for reduced SPs gene expression after surfactant/PxB treatment topical use of PxB should be considered with caution.

[1]  A. Calkovska,et al.  Short-Term versus Long-Term Culture of A549 Cells for Evaluating the Effects of Lipopolysaccharide on Oxidative Stress, Surfactant Proteins and Cathelicidin LL-37 , 2020, International journal of molecular sciences.

[2]  R. Veldhuizen,et al.  New insights into exogenous surfactant as a carrier of pulmonary therapeutics. , 2019, Biochemical pharmacology.

[3]  J. Johansson,et al.  Natural Derived Surfactant Preparation As a Carrier of Polymyxin E for Treatment of Pseudomonas aeruginosa Pneumonia in a Near-Term Rabbit Model. , 2019, Journal of aerosol medicine and pulmonary drug delivery.

[4]  A. Calkovska,et al.  Alveolar-Capillary Membrane-Related Pulmonary Cells as a Target in Endotoxin-Induced Acute Lung Injury , 2019, International journal of molecular sciences.

[5]  S. Meng,et al.  Effect of surfactant administration on outcomes of adult patients in acute respiratory distress syndrome: a meta-analysis of randomized controlled trials , 2019, BMC Pulmonary Medicine.

[6]  J. Li,et al.  Intracellular localization of polymyxins in human alveolar epithelial cells , 2018, The Journal of antimicrobial chemotherapy.

[7]  A. Calkovska,et al.  The Perturbation of Pulmonary Surfactant by Bacterial Lipopolysaccharide and Its Reversal by Polymyxin B: Function and Structure , 2018, International journal of molecular sciences.

[8]  Wei Zhang,et al.  GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway , 2018, Mediators of inflammation.

[9]  A. Calkovska,et al.  Pulmonary surfactant and bacterial lipopolysaccharide: the interaction and its functional consequences. , 2017, Physiological research.

[10]  Fanfan Zhou,et al.  Potential Toxicity of Polymyxins in Human Lung Epithelial Cells , 2017, Antimicrobial Agents and Chemotherapy.

[11]  Jinle Lin,et al.  Apoptosis and surfactant protein-C expression inhibition induced by lipopolysaccharide in AEC II cell may associate with NF-κB pathway. , 2017, The Journal of toxicological sciences.

[12]  E. Pessoa,et al.  Polymyxin B Nephrotoxicity: From Organ to Cell Damage , 2016, PloS one.

[13]  M. Valvano,et al.  Lipopolysaccharide modification in Gram-negative bacteria during chronic infection. , 2016, FEMS microbiology reviews.

[14]  X-J Zhang,et al.  The localization of SP-B and influences of lipopolysaccharide on it. , 2016, European review for medical and pharmacological sciences.

[15]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[16]  Fanfan Zhou,et al.  Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. , 2015, The Journal of antimicrobial chemotherapy.

[17]  R. Mallampalli,et al.  The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections. , 2015, Annals of the American Thoracic Society.

[18]  T. Hoffmann,et al.  DPP4 Inhibitors increase differentially the expression of surfactant proteins in Fischer 344 rats , 2014, Acta physiologica.

[19]  M. Kemp,et al.  Polymyxin B Agonist Capture Therapy for Intrauterine Inflammation , 2014, Reproductive Sciences.

[20]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[21]  L. Ortiz,et al.  LPS-treated macrophage cytokines repress surfactant protein-B in lung epithelial cells. , 2013, American journal of respiratory cell and molecular biology.

[22]  M. Rüdiger,et al.  Pulmonary Surfactant Preserves Viability of Alveolar Type II Cells Exposed to Polymyxin B In Vitro , 2013, PloS one.

[23]  H. Trübel,et al.  Lipopolysaccharide-induced acute lung injury in rats: comparative assessment of intratracheal instillation and aerosol inhalation. , 2013, Toxicology.

[24]  Dave Singh,et al.  Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. , 2012, British journal of clinical pharmacology.

[25]  J. Li,et al.  Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. , 2012, The Journal of antimicrobial chemotherapy.

[26]  S. Sanyal,et al.  Cycloxygenase Inhibition Enhances the Effects of Surfactant Therapy in Endotoxin-Induced Rat Model of ARDS , 2011, Inflammation.

[27]  Ta-Liang Chen,et al.  Lipopolysaccharide induces apoptotic insults to human alveolar epithelial A549 cells through reactive oxygen species-mediated activation of an intrinsic mitochondrion-dependent pathway , 2011, Archives of Toxicology.

[28]  Sanford Weisberg,et al.  An R Companion to Applied Regression , 2010 .

[29]  Jie Fan,et al.  Association of Toll-Like Receptor Signaling and Reactive Oxygen Species: A Potential Therapeutic Target for Posttrauma Acute Lung Injury , 2010, Mediators of inflammation.

[30]  C. Bosquillon,et al.  Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs? , 2010, Journal of pharmaceutical sciences.

[31]  R. Andersson,et al.  Variation of lipopolysaccharide-induced acute lung injury in eight strains of mice , 2010, Respiratory Physiology & Neurobiology.

[32]  E. Herting,et al.  Prophylactic Intratracheal Polymyxin B/Surfactant Prevents Bacterial Growth in Neonatal Escherichia coli Pneumonia of Rabbits , 2010, Pediatric Research.

[33]  T. Espevik,et al.  Meconium-induced release of cytokines is mediated by the TRL4/MD-2 complex in a CD14-dependent manner. , 2010, Molecular immunology.

[34]  Susan E Wert,et al.  Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. , 2010, Annual review of medicine.

[35]  E. Ozyilmaz,et al.  Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? , 2010, Intensive Care Medicine.

[36]  Z. Sever-Chroneos,et al.  Pulmonary Surfactant: An Immunological Perspective , 2009, Cellular Physiology and Biochemistry.

[37]  R. Niven,et al.  KL4‐surfactant prevents hyperoxic and LPS‐induced lung injury in mice , 2006, Pediatric pulmonology.

[38]  C. Booy,et al.  Ropivacaine decreases inflammation in experimental endotoxin-induced lung injury. , 2006 .

[39]  J. Johansson,et al.  Polymyxin B/Pulmonary Surfactant Mixtures Have Increased Resistance to Inactivation by Meconium and Reduce Growth of Gram-Negative Bacteria In Vitro , 2006, Pediatric Research.

[40]  M. Falagas,et al.  Toxicity of polymyxins: a systematic review of the evidence from old and recent studies , 2006, Critical care.

[41]  J. Johansson,et al.  Biophysical and Physiological Properties of Porcine Surfactant Enriched with Polymyxin B , 2005, Neonatology.

[42]  Xiangdong Wang,et al.  Lung Inflammatory Responses and Hyperinflation Induced by an Intratracheal Exposure to Lipopolysaccharide in Rats , 2004, Lung.

[43]  J. Johansson,et al.  Interaction of Pulmonary Surfactant Protein C with CD14 and Lipopolysaccharide , 2003, Infection and Immunity.

[44]  S. Holland,et al.  In vivo lipid‐derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  J. Johansson,et al.  Structural Basis for Interactions between Lung Surfactant Protein C and Bacterial Lipopolysaccharide* , 2002, The Journal of Biological Chemistry.

[46]  V. Glumoff,et al.  Regulation of surfactant proteins by LPS and proinflammatory cytokines in fetal and newborn lung. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[47]  C. Ruppert,et al.  Surfactant alteration and replacement in acute respiratory distress syndrome , 2001, Respiratory research.

[48]  J. Schulte‐Mönting,et al.  Alveolar Recruitment Promotes Homogeneous Surfactant Distribution in a Piglet Model of Lung Injury , 2001, Pediatric Research.

[49]  E. Ingenito,et al.  Decreased surfactant protein-B expression and surfactant dysfunction in a murine model of acute lung injury. , 2001, American journal of respiratory cell and molecular biology.

[50]  B. Persson,et al.  Pulmonary surfactant protein B: a structural model and a functional analogue. , 2000, Biochimica et biophysica acta.

[51]  M. R. Brown,et al.  Antimicrobial properties of liposomal polymyxin B. , 1999, The Journal of antimicrobial chemotherapy.

[52]  H. Haagsman,et al.  Efficacy of Curosurf in a rat model of acute respiratory distress syndrome. , 1998, The European respiratory journal.

[53]  K. Brogden,et al.  Complexing of bacterial lipopolysaccharide with lung surfactant , 1986, Infection and immunity.

[54]  L. Greenfield,et al.  Effects of endotoxin on pulmonary capillary permeability and surfactant. , 1968, Surgical forum.